Floatz logo

Jab-2485

ARID1A Gene Mutation

Jacobio Pharmaceuticals Co., Ltd.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the ARID1A Gene Mutation cohort.

Asset / SponsorPhaseRating
Tazemetostat
Prisma Health-Upstate
Phase 2CCC
Irinotecan
University of Oklahoma
Phase 2CCC
(+)-VINCRISTINE
University of Oklahoma
Phase 2CCC
Niraparib
University of Oklahoma
Phase 2CCC
nxp800
Nuvectis Pharma, Inc.
Phase 1CC

Same molecule, other indications

Jab-2485 is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
estrogen-receptor positive breast cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →